Cargando…
Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation
Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. T315I Bcr-Abl is the most notorious point mutation to elicit acquired resistance to imatinib (IM), leading to poor prognosis. Therefore, it is urgent to search for additional approaches and targeting strateg...
Autores principales: | Lan, Xiaoying, Zhao, Chong, Chen, Xin, Zhang, Peiquan, Zang, Dan, Wu, Jinjie, Chen, Jinghong, Long, Huidan, Yang, Li, Huang, Hongbiao, Wang, Xuejun, Shi, Xianping, Liu, Jinbao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5550844/ https://www.ncbi.nlm.nih.gov/pubmed/28682311 http://dx.doi.org/10.1038/cddis.2017.284 |
Ejemplares similares
-
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016) -
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
por: Zhao, Chong, et al.
Publicado: (2016) -
Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases
por: Zhao, Chong, et al.
Publicado: (2017) -
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms
por: Chen, Xin, et al.
Publicado: (2014) -
Platinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibition
por: Huang, Hongbiao, et al.
Publicado: (2017)